Session Information
-
WCLC 2017
18th World Conference on Lung Cancer
Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan
Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18
-
+
JCSE 01 - Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West
- 07:30 - 11:30
- 10/15/2017
- Location: F203 (Annex Hall)
- Type: Joint Session IASLC/CSCO/CAALC
- Track: Immunology and Immunotherapy
- Moderators:C. Bai, Fred R. Hirsch, Tony SK Mok, Yi-Long Wu
-
+
JCSE 01.27 - Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial
11:30 - 11:30 | Presenter: Tony SK Mok | Author(s): Solange Peters, D. Ross Camidge, Shirish M Gadgeel, S.I. Ou, D. Kim, Rafal Dziadziuszko, F. De Marinis, R. Sangha, A. Zeaiter, J. Noe, E. Nueesch, T. Liu, I. Loftin, C. Williams, Alice Shaw
- Abstract
Loading...
-
+
P1.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P1.01-001 - Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK+ NSCLC in the ALTA Trial
09:30 - 09:30 | Presenter: D. Ross Camidge | Author(s): M. Tiseo, Myung-Ju Ahn, Karen L Reckamp, K.H. Hansen, Sang-We Kim, Rudolf M Huber, Howard L West, H.J. Groen, Maximilian Johannes Hochmair, Natasha B Leighl, Scott N. Gettinger, Corey J Langer, Luis Paz-Ares, Egbert F Smit, E.S. Kim, W. Reichmann, D. Kerstein, D. Kim
- Abstract
Loading... -
+
P1.01-004 - Hypertension With Brigatinib: Experience in ALTA, a Randomized Phase 2 Trial in Crizotinib-Refractory ALK+ NSCLC
09:30 - 09:30 | Presenter: D. Ross Camidge | Author(s): Myung-Ju Ahn, Karen L Reckamp, Howard L West, Rudolf M Huber, Corey J Langer, Lyudmila A Bazhenova, Natasha B Leighl, W. Reichmann, D. Kerstein, D. Kim
- Abstract
Loading... -
+
P1.01-005 - Overall Survival (OS) After Disease Progression (PD) on Brigatinib in Patients With Crizotinib-Refractory ALK+ NSCLC in ALTA
09:30 - 09:30 | Presenter: Corey J Langer | Author(s): H. Huang, W. Reichmann, S. Lustgarten, D. Kerstein, D. Ross Camidge
- Abstract
Loading... -
+
P1.01-012 - Ceritinib in Anaplastic Lymphoma Kinase (ALK)+ NSCLC Patients Pretreated With Only Crizotinib: ASCEND-1 Subgroup Analysis
09:30 - 09:30 | Presenter: Alice Shaw | Author(s): D. Kim, Ben J Solomon, Enriqueta Felip, Gregory J Riely, Martin Schuler, Daniel SW Tan, Laura Q Chow, D. Ross Camidge, P. Urban, C. Ortmann, I. Malet, R. Mehra
- Abstract
Loading... -
+
P1.01-016 - Next-Generation Sequencing Shows Mechanisms of Intrinsic Resistance in ALK-Positive NSCLC Patients Treated with Crizotinib
09:30 - 09:30 | Presenter: Ben J Solomon | Author(s): J. Soria, Fiona Blackhall, Alice Shaw, D. Ross Camidge, D. Kim, Tony SK Mok, J. Fernandez-Banet, Z. Kan, S. Li, Y. Liu, S.N. Ho
- Abstract
Loading...
-
+
MA 02 - Emerging Targets
- 11:00 - 12:30
- 10/16/2017
- Location: Room 511 + 512
- Type: Mini Oral
- Track: Clinical Design, Statistics and Clinical Trials
- Moderators:Ravi Salgia, Shun Lu
-
+
MA 02.10 - Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC
12:05 - 12:10 | Presenter: Jonathan Wade Goldman | Author(s): E. Angevin, J. Strickler, D. Ross Camidge, R. Heist, D. Morgensztern, M. Barve, H. Yue, J. Beaulieu, M. Motwani, D. Afar, L. Naumovski, Karen Kelly
- Abstract
Loading...
-
+
OA 05 - Next Generation TKI
- 15:45 - 17:30
- 10/16/2017
- Location: Room 301 + 302
- Type: Oral
- Track: Advanced NSCLC
- Moderators:James Chih-Hsin Yang, Fiona Blackhall
-
+
OA 05.05 - Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial
16:30 - 16:40 | Presenter: Myung-Ju Ahn | Author(s): D. Ross Camidge, M. Tiseo, Karen L Reckamp, K.H. Hansen, Sang-We Kim, Rudolf M Huber, Howard L West, H.J. Groen, Maximilian Johannes Hochmair, Natasha B Leighl, Scott N. Gettinger, Corey J Langer, Luis Paz-Ares, Egbert F Smit, E.S. Kim, W. Reichmann, D. Kerstein, D. Kim
- Abstract
Loading...
-
+
P2.02 - Biology/Pathology
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
-
+
P2.02-011 - Clinical and Molecular Features of Lung Cancers with Increased FGFR1 mRNA and/or Gene Copy Number
09:30 - 09:30 | Presenter: Terry L. Ng | Author(s): Hui Yu, E. York, S. Leedy, D. Gao, L. Heasley, Fred R. Hirsch, D. Ross Camidge
- Abstract
Loading...
-
+
P2.07 - Immunology and Immunotherapy
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
-
+
P2.07-034 - Health Status in Patients with Small-Cell Lung Cancer Treated with Nivolumab Alone or Combined with Ipilimumab: CheckMate 032
09:30 - 09:30 | Presenter: D. Ross Camidge | Author(s): A. Ardizzoni, A.F. Farago, A. Atmaca, Emiliano Calvo, F. Taylor, B. Bennett, G. Selvaggi, A. Pieters, J.R. Penrod, Yong Yuan
- Abstract
Loading...
-
+
MA 07 - ALK, ROS and HER2
- 15:45 - 17:30
- 10/17/2017
- Location: Room 316
- Type: Mini Oral
- Track: Advanced NSCLC
- Moderators:Robert C. Doebele, J.C. Ho
-
+
MA 07.01 - Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial
15:45 - 15:50 | Presenter: Tony SK Mok | Author(s): Solange Peters, D. Ross Camidge, Shirish M Gadgeel, S. Ignatius Ou, D. Kim, Rafal Dziadziuszko, F. De Marinis, R. Sangha, A. Zeaiter, J. Noe, E. Nueesch, T. Liu, Isabell Loftin, C. Williams, Alice Shaw
- Abstract
Loading...
-
+
ES 08 - Molecular Diagnostics and Targeted Therapy
- 11:00 - 12:30
- 10/18/2017
- Location: Main Hall
- Type: Educational Session
- Track: Chemotherapy/Targeted Therapy
- Moderators:Kwun M Fong, David Planchard
-
+
ES 08.03 - Update of the Management of ALK-Positive NSCLC
11:30 - 11:45 | Presenter: D. Ross Camidge
- Abstract
Loading...
-
+
OA 12 - Emerging Genomic Targets
- 11:00 - 12:30
- 10/18/2017
- Location: F203 + F204 (Annex Hall)
- Type: Oral
- Track: Advanced NSCLC
- Moderators:H. Akita, Maurice Pérol
-
+
OA 12.06 - Plasma Genomic Profiling and Outcomes of Patients with MET Exon 14-Altered NSCLCs Treated with Crizotinib on PROFILE 1001
11:50 - 12:00 | Presenter: Alexander Drilon | Author(s): J.W. Clark, J. Weiss, Sai-Hong Ignatius Ou, D. Ross Camidge, Ben J Solomon, G. Otterson, L.C. Villaruz, Gregory J Riely, R. Heist, G.I. Shapiro, D.A. Murphy, Y. Liu, S.C. Wang, T. Usari, K.D. Wilner, Paul K. Paik
- Abstract
Loading...